Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician.
about
Emerging and investigational drugs for premature ejaculationA comprehensive approach toward novel serum biomarkers for benign prostatic hyperplasia: the MPSA Consortium.Clinical pearls in men's health.The effectiveness of dried cranberries ( Vaccinium macrocarpon) in men with lower urinary tract symptoms.Benign prostatic hyperplasia: treatment in primary care.Stromally expressed c-Jun regulates proliferation of prostate epithelial cells.5alpha-reductase inhibition for men with enlarged prostate.Silodosin : a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia.Recent advances in the design and synthesis of prazosin derivatives.Current role of treatment in men with lower urinary tract symptoms combined with overactive bladder.The Effect of LUTS/BPH and Treatments on Ejaculatory Function.Effect of 5-alpha Reductase Inhibitor on Storage Symptoms in Patients with Benign Prostatic Hyperplasia.Effect of Selective Prostaglandin E2 EP2 Receptor Agonist CP-533,536 on Voiding Efficiency in Rats with Midodrine-Induced Functional Urethral Obstruction.Antiproliferative and cytotoxic activity of extracts from Cistus incanus L. and Cistus monspeliensis L. on human prostate cell lines.Androgenic to oestrogenic switch in the human adult prostate gland is regulated by epigenetic silencing of steroid 5α-reductase 2.Open-label, 9-month extension study investigating the uro-selective alpha-blocker silodosin in men with LUTS associated with BPH.Initial Use of High-Dose Anticholinergics Combined with Alpha-Blockers for Male Lower Urinary Tract Symptoms with Overactive Bladder: A Prospective, Randomized Preliminary Study.An open-label, prospective interventional study of the tolerability and efficacy of 0.4 mg oral tamsulosin oral controlled absorption system in men with lower urinary tract symptoms associated with benign prostatic hyperplasia who are unsatisfied wiMetformin: an anti-proliferative agent and methylation regulator in treating prostatic disease?Synergistic Effect by Co-Administration of Tamsulosin and Solifenacin on Bladder Activity in Rats.
P2860
Q28078002-CB19B1F7-CBF4-4F68-9557-8C45352AAD46Q33320106-99E3E99C-5D1C-47CF-AB55-C25BD2DFFCA6Q33951568-612EAEA2-B479-4198-82E3-851CD25F3CDDQ34023693-DFE222B3-4EF6-4444-BEEE-40E7D117D922Q35021669-8BF4231E-DBD9-440E-84A3-8E05C8EC9C6AQ36007409-D1E8A137-A92C-4244-9B9F-979C8F30BDC2Q36892851-C3D176C7-E448-41D4-86C5-57D7A0640E14Q38038271-EA94D4C5-901D-4415-860B-3CBD928B95E1Q38089804-CD71D556-BE84-4EFD-AD4B-CA37E7D21429Q38230461-85C8EF08-6CA3-4911-BAC8-B21C3E75ECA5Q38815285-213C7F72-3953-46FF-8A43-A3103DFBD8DDQ39015782-626E6B64-167E-4C0F-8C4B-BC6DA02B3319Q39173562-56DC9BCD-F45F-4CBF-A99C-3D353D183C37Q39693746-BE6F82F8-6AA2-424F-BCE0-B624224B1F28Q47756626-C6E3AA21-CBC1-4F45-AC93-0579897B03B5Q48048242-B3CD1BE1-3C7D-431C-9965-9FC6E4FAA1DAQ48835559-745BD3CF-0F3F-4460-9074-6AAF9802CCE0Q49569643-5B512875-2811-49D4-855B-BCEB810D93D8Q50103863-E6364432-417D-476F-8A48-F0F6B4982B9FQ51371258-24BC95FA-1B47-4670-B5AC-A107C3F9BD09
P2860
Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Pharmacological therapy of ben ...... for the practising clinician.
@ast
Pharmacological therapy of ben ...... for the practising clinician.
@en
type
label
Pharmacological therapy of ben ...... for the practising clinician.
@ast
Pharmacological therapy of ben ...... for the practising clinician.
@en
prefLabel
Pharmacological therapy of ben ...... for the practising clinician.
@ast
Pharmacological therapy of ben ...... for the practising clinician.
@en
P2860
P1433
P1476
Pharmacological therapy of ben ...... for the practising clinician.
@en
P2860
P304
P356
10.1111/J.1464-410X.2004.05022.X
P577
2004-09-01T00:00:00Z